source · application/json
source_40075b7fa7b4455b
sha256 c58ef1a0cb2b9027432fe78fc81a7aa52644ce8c9fce183b4274a78206cc046d
by researka:v2 · 2026-05-27 18:33:42.734053+04:00
{"publication_id": "4ff5f065-8b09-4580-9cbc-da14dbcaa1fa", "traces": [{"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "What does the current evidence establish about Aspirin Geroprotection and human geroscience? This synthesis tests the thesis that evidence for Aspirin geroprotection is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Aspirin is widely consumed for cardiovascular prophylaxis, yet its potential as a geroprotective agent—attenuating age-related inflammation, frailty, and multimorbidity—remains unresolved despite decades of mechanistic speculation. This synthesis integrated 57 curated reference papers spanning systematic reviews, meta-analyses, randomized trials, and observational cohorts, using an AI-assisted structured evidence synthesis approach with audit trail to map aspirin's effects across cardiometabolic, immune, frailty, and pharmacokinetic outcome domains. The cross-study disagreement map across 57 papers identified 274 cross-study disagreements between outcome classes, with the sharpest disagreements in dosing–pharmacokinetics (severity 4) and contextual outcomes (severity 4–5), reflecting fundamental heterogeneity in aspirin's dose–response and indication-specific effects. While aspirin demonstrates mechanistic plausibility for geroprotection through COX-mediated inflammation resolution and skeletal muscle inflammation hastening following acute injury, the current human evidence—including large randomized trials and cohort studies spanning thousands of participants—do", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual other, dosing and pharmacokinetics, frailty, immune, immune and inflammation, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "| Contextual Other | n=17; claims=1063 | null signal in 10/17 sources | 11 indirect; 6 review | limited corpus depth in this outcome class |", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "| Dosing and Pharmacokinetics | n=13; claims=1147 | null signal in 7/13 sources | 11 indirect; 2 review | limited corpus depth in this outcome class |", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "| Immune and Inflammation | n=5; claims=194 | null signal in 3/5 sources | 2 indirect; 3 review | limited corpus depth in this outcome class |", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "| Cardiometabolic | n=3; claims=125 | null signal in 3/3 sources | 1 direct; 1 indirect; 1 review | limited corpus depth in this outcome class |", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "| Safety and Comorbidity | n=3; claims=263 | null signal in 3/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "The cardiometabolic outcome class includes evidence from a randomized controlled trial, a meta-analysis of observational cohorts, and a lifestyle intervention study, all examining interventions with potential geroprotective pathways. The observational cohort synthesis by Zhou 2026 is a meta-analysis evaluating the Mediterranean diet with high-phenolic extra virgin olive oil in adults with non-dialysis chronic kidney disease, focusing on kidney function and inflammation. The indirect, observational study by Yerrabelli 2026 examined lifestyle intervention in older adults with metabolic disease, reporting on endpoints including weight loss and glycemic control. Evidence per study is detailed in Table 2 (Per-Study Endpoint Evidence).", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Quantitative findings across these studies consistently support intervention-associated improvements in cardiometabolic markers. These exact numeric values from the sources are tabulated in Table 2.", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Mechanistically, the observed cardiometabolic benefits across these interventions converge on shared pathways of inflammation reduction and metabolic improvement. The clinical RCT by Abassi 2026 directly links walking to reduced inflammation, while Zhou 2026's meta-analysis highlights the anti-inflammatory potential of a high-phenolic diet in a chronic kidney disease population. Preclinical data and the mechanistic human study framework of Yerrabelli 2026 suggest lifestyle intervention attenuates endoplasmic reticulum stress and inflammation, enhancing immune cell identity. These mechanistic substrates—modulation of inflammatory pathways like C-reactive protein and improvement of insulin sensitivity—are central to the hypothesized geroprotective action of interventions on cardiometabolic health.", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Within the corpus, the evidence shows broad agreement on the direction of cardiometabolic benefit, though the specific interventions and populations differ. By contrast, while all point toward improvement, the heterogeneity in interventions (walking vs. diet vs. multifactorial lifestyle change), study designs (RCT vs. meta-analysis vs. observational), and target populations (postmenopausal women vs. CKD patients vs. older adults with metabolic disease) precludes a unified quantitative estimate for aspirin's role. This underscores the need for focused RCTs on aspirin's specific geroprotective effects.", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "The evidence base for aspirin in various clinical contexts draws heavily from meta-analyses of dual antiplatelet therapy (DAPT) regimens following percutaneous coronary intervention (PCI). Complementing this, a separate meta-analysis of randomized trials evaluating early aspirin withdrawal in high-risk post-PCI patients found that aspirin cessation was associated with a significant reduction in major bleeding (P < 0.001) without a concomitant increase in ischemic events (Navarese 2026). These findings collectively suggest that within the specific context of post-PCI management, aspirin's role may be modifiable without catastrophic ischemic consequence, a nuance critical for assessing its broader geroprotective utility.", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "When examining aspirin monotherapy against alternatives, the evidence presents mixed signals. This divergence highlights that aspirin's comparative efficacy is highly dependent on the specific clinical indication and patient population.", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "A significant within-corpus tension exists regarding aspirin's net benefit profile. While several analyses report null findings for aspirin-based regimens compared to alternatives in specific endpoints (Saeed 2026; Stirum 2026; Hou 2026), other data suggest potential harm. For instance, a study on pregnant individuals with increased heat exposure demonstrated that aspirin use was associated with a negative effect direction on preterm birth risk, presenting a potential adverse pathway that could counter any theoretical geroprotective benefits in susceptible subpopulations (Meltzer 2026). This disagreement underscores that the overall risk-benefit calculus for aspirin as a geroprotector is not straightforward and may be modulated by environmental and individual risk factors not typically considered in aging research.", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "The evidence base for aspirin dosing and pharmacokinetics encompasses multiple clinical contexts, ranging from pregnancy-related outcomes to cardiovascular and neuropsychiatric indications. Across the corpus, 13 studies addressed these pharmacological considerations, including meta-analytic syntheses, clinical trials, and observational cohorts. These pregnancy-focused studies collectively enrolled thousands of women and examined doses ranging from 75 mg to 162 mg daily.", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Within the corpus, notable tensions emerge regarding aspirin's dose-dependent effects. Wang 2026 examined ticagrelor combined with aspirin for neurological protection without providing specific effect estimates, and the overall pattern across these studies suggests that aspirin's pharmacological actions are highly context-dependent rather than uniformly beneficial.", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "The evidence on aspirin's effect on frailty status is anchored in a post hoc secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) randomised clinical trial. The population comprised participants from the large-scale ASPREE cohort, and the trial's design allowed for assessment of frailty transition as a functional endpoint over the follow-up period. The study aimed to determine if a geroprotective effect of aspirin could be detected in this vulnerable subgroup.", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Quantitative findings from this clinical RCT were uniformly null across the key frailty-related endpoints. These p-values, detailed in Table 2, indicate no robust evidence of benefit. The consistent lack of statistical significance across multiple endpoints suggests that, within this trial's parameters, aspirin did not meaningfully alter the trajectory from prefrail or frail to a more robust state.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Mechanistically, the rationale for aspirin's potential geroprotective action on frailty would involve its anti-inflammatory and antiplatelet properties, which could theoretically modulate the chronic low-grade inflammation (inflammaging) associated with sarcopenia and functional decline. However, the clinical RCT evidence from ASPREE does not support this pathway translating into a functional benefit for frailty reversal. The disconnect between plausible biological mechanisms and the observed null clinical outcome underscores the complexity of targeting multifactorial age-related syndromes with a single pharmacological agent.", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "The evidence base for aspirin's immune-modulating properties was assessed through a synthesis of systematic reviews, meta-analyses, and observational cohorts. A central finding from preclinical research indicates that aspirin, at a dose of 30 mg/kg/day, hastens the resolution of cellular inflammation in skeletal muscle following acute injury (Lu 2026). This mechanistic action is contrasted by data from human studies. These findings from indirect comparators contextualize the challenge in isolating a specific anti-inflammatory effect for aspirin within complex human physiology.", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Quantitative findings from the included studies present a heterogeneous picture of inflammation's role in geroprotection. In a different context, a systematic review linked ultra-processed food intake in pediatric obesity to inflammatory and metabolic dysregulation, though specific p-values were not extracted (Porri 2026). A review of air pollution and dementia reported that C-reactive protein mediated 42.9% of the association between particulate matter exposure and Alzheimer's disease risk (P = 0.003) (Zhao 2026). These studies underscore the multifactorial nature of age-related inflammation but do not directly evaluate aspirin.", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Mechanistically, aspirin's proposed anti-inflammatory action via cyclooxygenase inhibition aligns with pathways implicated in aging, such as the resolution of neutrophilic inflammation (Lu 2026). However, human evidence for this specific mechanism in a geroprotective context is sparse. One observational study on long-term anakinra therapy in Schnitzler syndrome reported remission of systemic inflammation, with p-values < 0.05 and < 0.01 for key biomarkers, but this targeted biologic therapy is not analogous to aspirin (Sikora 2026). A systematic review on lupus nephritis further highlights that tubulointerstitial inflammation is a critical determinant of renal function decline, emphasizing inflammation's broad pathological role (Donato 2026). Thus, while the mechanistic substrate linking aspirin to inflammation resolution exists, direct clinical geroprotection data are absent from this corpus.", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Within the corpus, notable tensions exist regarding the directness and specificity of evidence. The preclinical finding of aspirin promoting muscle inflammation resolution (Lu 2026) stands in contrast to the null or unclear effects observed in human intervention reviews for other supplements like creatine (Camargo 2026) and anthocyanins (Mekhora 2026). A methodological tension is apparent between reviews that report significant inflammatory mediation, such as CRP's role in air pollution-dementia pathways (Zhao 2026), and those that find no significant effect of interventions on systemic markers, such as the null acute effect of creatine on CRP (Camargo 2026). Furthermore, the observational cohort demonstrating inflammation's link to cognitive glymphatic changes (Ye 2025) is mechanistically plausible but does not establish causality or test a therapeutic intervention like aspirin. The reviewed evidence on dexamethasone dosing for perioperative inflammation (Zhu 2026b) and clobetasol for ocular inflammation (Levenson 2026) pertains to specific clinical contexts rather than systemic, age-related inflammation relevant to geroprotection.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "The corpus for immune and inflammatory outcomes includes five reference papers examining aspirin's effects through diverse study designs and populations. A clinical RCT by Areia 2025 enrolled thirty-two pregnant women receiving low-dose aspirin (LDA) to evaluate immune cell modulation, with analyses of natural killer (NK) cell subsets performed at the second trimester versus four weeks after LDA initiation. Observational data from Gwenzi 2026 examined personalized vitamin D3 supplementation effects on inflammation in colorectal cancer patients who underwent surgery within the past year, while Sattui 2026 described the ongoing Reducing Inflammation for Greater Health Trial (RIGHT), which will enroll participants aged 70 years and older with low to moderate physical function. The remaining evidence comprises systematic reviews and meta-analyses: Zhang 2026 evaluated the systemic immune-inflammation index (SII) as a predictor of atrial fibrillation recurrence, and He 2026 assessed fecal microbiota transplantation effects on liver inflammation indicators in metabolic-associated fatty liver disease.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Quantitative findings across the corpus present a mixed pattern. Zhang 2026 reported that high preprocedural SII was significantly associated with atrial fibrillation recurrence with a relative risk of 2.3 (P < 0.001 across multiple analyses).", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Mechanistically, the evidence suggests aspirin may modulate immune cell populations and inflammatory pathways through distinct biological mechanisms. Areia 2025 demonstrated a shift toward tolerogenic NK cell phenotypes (CD56 bright) with concurrent reduction in total NK cells, consistent with anti-inflammatory immunomodulation. The mechanistic substrate underlying He 2026's findings on fecal microbiota transplantation points to gut-liver axis modulation as a pathway for reducing hepatic inflammation, with significant mean differences in ALT levels. Sattui 2026's RIGHT trial design targets inflammation specifically in older adults with functional limitations, recognizing that inflammaging represents a key geroprotection target, though the trial is ongoing and no efficacy data are yet available from this population.", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1007/s11357-025-01839-8", "study": "Flensted-Jensen 2025", "url": "https://doi.org/10.1007/s11357-025-01839-8"}, {"doi": "10.1002/ccd.70463", "study": "Saeed 2026", "url": "https://doi.org/10.1002/ccd.70463"}, {"doi": "10.1177/10760296251410933", "study": "Zhu 2026", "url": "https://doi.org/10.1177/10760296251410933"}, {"doi": "10.1371/journal.pmed.1004995", "study": "Navarese 2026", "url": "https://doi.org/10.1371/journal.pmed.1004995"}, {"doi": "10.1186/s12884-024-06413-2", "study": "Yan 2024", "url": "https://doi.org/10.1186/s12884-024-06413-2"}], "claim": "Within-corpus tensions emerge when comparing the null effect directions reported for aspirin-specific interventions against the positive signals from related immune-inflammatory research. Zhang 2026 demonstrated that elevated SII predicts atrial fibrillation recurrence (RR = 2.3, P < 0.001), suggesting systemic inflammation worsens cardiovascular outcomes, but this does not establish aspirin's capacity to reduce SII or improve geroprotective endpoints. A systematic review and meta-analysis evaluated the efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention (PCI). This analysis included a GRADE assessment and trial sequential analysis, focusing on long-term survival endpoints in adults with established cardiovascular disease.", "claim_id": "claim_30"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "4ff5f065-8b09-4580-9cbc-da14dbcaa1fa",
"researka_submission_id": "2dd9f448-4066-44fb-8390-eaed8003de5e",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/4ff5f065-8b09-4580-9cbc-da14dbcaa1fa/sidecars/citation_traces.json"
}